PCM
CADL icon

Portolan Capital Management’s Candel Therapeutics CADL Stock Holding History

Portolan Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36M Buy
3,490,398
+596,073
+21% +$4.5M 1.35% 20
2026
Q1 		$14.2M Buy
2,894,325
+1,198,958
+71% +$6.52M 0.75% 44
2025
Q4 		$9.58M Buy
1,695,367
+311,225
+22% +$1.67M 0.51% 73
2025
Q3 		$7.06M Sell
1,384,142
-237,586
-15% -$1.37M 0.38% 78
2025
Q2 		$8.21M Buy
1,621,728
+740,544
+84% +$3.81M 0.51% 63
2025
Q1 		$4.98M Buy
881,184
+127,439
+17% +$1.04M 0.38% 73
2024
Q4 		$6.54M Buy
+753,745
New +$4.45M 0.44% 74

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return

Portolan Capital Management's CADL Position: Q2 2026 in Review

Portolan Capital Management increased its Candel Therapeutics (CADL) stake by 21% in Q2 2026, buying an estimated $4.5M and bringing the position to 3,490,398 shares worth $36M. The position accounts for 1.35% of the portfolio, ranked #20.

Portolan Capital Management first reported a position in CADL in Q4 2024 and has held it in 7 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Portolan Capital Management held 3,490,398 shares of Candel Therapeutics worth $36M as of Q2 2026.
  • Portolan Capital Management bought 596,073 Candel Therapeutics shares in Q2 2026, an estimated $4.5M.
  • Candel Therapeutics made up 1.35% of Portolan Capital Management's portfolio in Q2 2026, its #20 holding.
  • Portolan Capital Management first reported a position in Candel Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Portolan Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.